FTC monitoring how drug companies react to patent cliff, official says 1 / 4 Dan Guarnera answers questions posed by Reuters Antitrust Correspondent Jody Godoy at Reuters Pharma USA in Phi...
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Acquire Media Monitor
pharmaceutical industry with a number of blockbuster drugs ?near the end of their patents, the FTC's head of antitrust enforcement said on ?Tuesday, as the agency looks to protect consumers from unfair prices. Monitoring the shift in the market brought about by patent expirations ?is part of the FTC's "laser focus" on healthcare, Dan Guarnera, director of the FTC's bureau of competition, said at Reuters Events' Pharma USA conference in Philadelphia. "We are always happy to hear concerns from market participants, including generics and patient groups to make sure that the entry of generics can happen as it's ?designed to under the patent ?laws," he said. Many of the top-selling U.S. drugs are set to lose their patent exclusivity by the end of the decade, including Merck's cancer drug Keytruda, ?Bristol Myers Squibb and Pfizer's blood thinner Eliquis and J&J's cancer drug Darzalex. Healthcare is an intentional focus area for the FTC, which has moved to block multiple deals in th
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- FDA Approves BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) from Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in DogsBusiness Wire
- FTC monitoring how drug companies react to patent cliff, official says [Yahoo! Finance]Yahoo! Finance
- Imfinzi EU Approval Expands AstraZeneca Gastric Cancer Reach For Investors [Yahoo! Finance]Yahoo! Finance
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Merck to Present New Data Reinforcing Long-Term Efficacy of GARDASIL®9 and GARDASIL® at the EUROGIN International Multidisciplinary HPV Congress 2026Business Wire
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 3/12/26 - Form 3
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- MRK's page on the SEC website